Cargando…

Effects of Sitagliptin on Pancreatic Beta-Cells in Type 2 Diabetes With Sulfonylurea Treatment: A Prospective Randomized Study

BACKGROUND: This prospective randomized, multicenter, open-label, comparative study was performed to analyze the effects of sitagliptin on glycemic control and maintenance of beta-cell function in patients with poorly controlled type 2 diabetes treated with low-dose glimepiride. METHODS: Forty-one p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Ai, Takei, Masahiro, Hiramatsu, Kunihide, Takeda, Teiji, Miyamoto, Takahide, Yamazaki, Masanori, Sato, Yoshihiko, Komatsu, Mitsuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306137/ https://www.ncbi.nlm.nih.gov/pubmed/30627273 http://dx.doi.org/10.14740/jocmr3632

Ejemplares similares

Efficacy of Combination Therapy With Sitagliptin and Low-Dose Glimepiride in Japanese Patients With Type 2 Diabetes
por: Ishii, Hiroaki, et al.
Publicado: (2014)

Efficacy of oral glucocorticoid and cyclosporine in a case of rituximab-refractory type B insulin resistance syndrome
por: Takei, Masahiro, et al.
Publicado: (2015)

A Case of Marine-Lenhart Syndrome with a Negative TSH Receptor Antibody Titer Successfully Treated with a Fixed, Low Dose of I(131)
por: Takei, Masahiro, et al.
Publicado: (2014)

Glucose‐stimulated insulin secretion: A newer perspective
por: Komatsu, Mitsuhisa, et al.
Publicado: (2013)

THU340 Efficacy And Safety Of Low-dose Spironolactone On Chronic Kidney Disease In Adults With Type 2 Diabetes: A Multicenter, Randomized Clinical Trial
por: Oiwa, Ako, et al.
Publicado: (2023)

Repression of insulin gene transcription by indirect genomic signaling via the estrogen receptor in pancreatic beta cells
por: Sekido, Takashi, et al.
Publicado: (2019)

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea
por: Kubota, Akira, et al.
Publicado: (2014)

Changes in serum uric acid levels as a predictor of future decline in renal function in older adults with type 2 diabetes
por: Shibata, Yusuke, et al.
Publicado: (2021)

Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy
por: Lorenzoni, Valentina, et al.
Publicado: (2017)

A Case of Severe and Recurrent Painless Thyroiditis Requiring Thyroidectomy
por: Ishii, Hiroaki, et al.
Publicado: (2013)

Intracellular free fatty acid upholds β-cell glucose competence: The role of peroxisome proliferator-activated receptor δ and mitochondrial metabolism
por: Takei, Masahiro, et al.
Publicado: (2015)

Gender-specific regulation of response to thyroid hormone in aging
por: Suzuki, Satoru, et al.
Publicado: (2012)

Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study
por: Mamza, Jil, et al.
Publicado: (2015)

SAT-139 Clinical Impact of Oral Semaglutide Compared with Sitagliptin in T2D on Metformin ± Sulfonylurea: The Pioneer 3 Trial
por: Rosenstock, Julio, et al.
Publicado: (2019)

Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis
por: Sharma, Manuj, et al.
Publicado: (2017)

Pancreatic Safety of Sitagliptin in the TECOS Study
por: Buse, John B., et al.
Publicado: (2017)

Characterization of Two Novel Retinoic Acid‐resistant Cell Lines Derived from HL‐60 Cells Following Long‐term Culture with all‐trans‐Retinoic Acid
por: Mori, Junichirou, et al.
Publicado: (1999)

Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
por: Ommen, Elizabeth S., et al.
Publicado: (2015)

Hypertrophic Pachymeningitis Associated with Myeloperoxidase-anti-neutrophil Cytoplasmic Antibodies Induced by Propylthiouracil
por: Koide, Sakiho, et al.
Publicado: (2022)

Interval walking training in type 2 diabetes: A pilot study to evaluate the applicability as exercise therapy
por: Kitajima, Kouhei, et al.
Publicado: (2023)

Erratum to: Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
por: Ommen, Elizabeth S., et al.
Publicado: (2015)

Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis
por: HOU, LIQIONG, et al.
Publicado: (2015)

Divergent Effects of Liraglutide, Exendin-4, and Sitagliptin on Beta-Cell Mass and Indicators of Pancreatitis in a Mouse Model of Hyperglycaemia
por: Mondragon, Angeles, et al.
Publicado: (2014)

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma
por: Toomey, Paul, et al.
Publicado: (2017)

Sulfonylureas: Asset or liability?
por: Lakhani, Om J., et al.
Publicado: (2015)

Sulfonylureas at the Glomerular Battlefield
por: Kalra, Sanjay, et al.
Publicado: (2018)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
por: Schernthaner, Guntram, et al.
Publicado: (2013)

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
por: Engel, S S, et al.
Publicado: (2010)

Sitagliptin-induced pancreatitis – a longer road than expected
por: Nelson, Matthew, et al.
Publicado: (2014)

Chronic Antidiabetic Sulfonylureas In Vivo: Reversible Effects on Mouse Pancreatic β-Cells
por: Remedi, Maria Sara, et al.
Publicado: (2008)

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma: erratum
Publicado: (2017)

Sulfonylurea action re‐revisited
por: Seino, Susumu, et al.
Publicado: (2010)

Sulfonylureas and their use in clinical practice
por: Sola, Daniele, et al.
Publicado: (2015)

A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin
por: Sue, Mariko, et al.
Publicado: (2013)

Sitagliptin-induced Pancreatitis: Chronic Use Would Not Spare You the Complication
por: Alkayali, Talal, et al.
Publicado: (2020)

Effectiveness of Nateglinide on In Vitro Insulin Secretion from Rat Pancreatic Islets Desensitized to Sulfonylureas
por: Hu, Shiling, et al.
Publicado: (2001)

Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force
por: Kalra, Sanjay, et al.
Publicado: (2018)

Sitagliptin-induced hemolysis
por: Bekur, Ragini, et al.
Publicado: (2010)

Sitagliptin-Associated Angioedema
por: Gosmanov, Aidar R., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vbrdjc52tlpoqtc60jp52dhrqq